SCHEMBL4303428

SCHEMBL4303428

OCCCCC[C@@H]1CCCNC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.48
HRH3 Q9Y5N1 3/20 0.45
KMT2A Q03164 2/20 0.43
HRH4 Q9H3N8 2/20 0.41
CHRNB2 P17787 2/20 0.40
CHRNB4 P30926 2/20 0.40
CHRNA3 P32297 2/20 0.40
CHRNA4 P43681 2/20 0.40
CPN1 P15169 1/20 0.39
CPB2 Q96IY4 1/20 0.39
EPHX1 P07099 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
ACP1 P24666 2/20 0.35
SLC6A1 P30531 2/20 0.34
SLC6A11 P48066 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC6A13 Q9NSD5 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12557625 1.00 NAAA (0.48) NAAAHRH3KMT2AHRH4CHRNB2
Hydrochloric Acid SCHEMBL5593326 0.98 NAAA (0.47) NAAAHRH3KMT2AHRH4CHRNB2
SCHEMBL2411749 0.98 HRH3 (0.46) NAAAHRH3KMT2AHRH4CHRNB2
SCHEMBL15358134 0.92 HRH3 (0.47) NAAAHRH3KMT2AHRH4CHRNB2
SCHEMBL1071426 0.92 HRH3 (0.47) NAAAHRH3KMT2AHRH4CHRNB2
SCHEMBL16925546 0.91 HRH3 (0.41) NAAAHRH3KMT2AHRH4CHRNB2
Hydrochloric Acid SCHEMBL7422319 0.90 HRH3 (0.46) NAAAHRH3KMT2AHRH4CHRNB2
Acetic Acid SCHEMBL1839982 0.90 NAAA (0.48) NAAAHRH3KMT2ACHRNB2CHRNB4
SCHEMBL11170648 0.90 HRH3 (0.51) NAAAHRH3KMT2AHRH4CHRNB2
SCHEMBL5253186 0.88 SLC6A1 (0.44) NAAAHRH3KMT2AHRH4CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807078-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2007-07-18 EP claimed
WO-2006042150-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-04-20 WO claimed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
WO-2007117557-A2 DIAMINOPROPANOL RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed
WO-2007117560-A2 PIPERIDINE AND MORPHOLINE RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 NAAA 650/4885HRH3 1149/4885KMT2A 4668/4885
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 NAAA 640/4885HRH3 1334/4885KMT2A 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.